Orphan drug supply: rare-disease medicines, sourced from Indian WHO-GMP origin.
Eculizumab, ataluren, nusinersen, ivacaftor, miglustat, sapropterin and the long tail of rare-disease therapies that the local market either does not stock, has discontinued, or has never registered. M Care is the manufacturer-side partner for hospital pharmacies, patient access programmes and rare-disease specialty importers running an orphan-drug single-batch import.
Orphan-designated. Patient-prioritised. Single-batch supportable.
Orphan drug supply sits at the intersection of regulatory pathway and humanitarian access. The EU's Orphan Designation under Regulation (EC) 141/2000, the UK's Early Access to Medicines Scheme (EAMS) and the FDA's Orphan Drug Act all create accelerated and special-access channels for medicines treating rare conditions. M Care operates as the Indian manufacturer-side bridge — sourcing the molecule, preparing the documentation, and handing the shipment to a destination importer who holds the regulatory authorisation locally.
Who the route serves
Hospital pharmacies running rare-disease centres of excellence (UK CMG networks, EU reference network ERNs, GCC tertiary referral hospitals). Patient access programmes operated by NORD-equivalent rare-disease NGOs. Paediatric haematology / metabolic / neuromuscular teams who need a strength or formulation that the local commercial pack does not carry.
Where we sit in it
Manufacturer-side. We are not the destination importer and we are not the prescriber. We are the Indian WHO-GMP facility's regulatory and commercial arm. The destination Wholesale Dealer's Licence holder pulls product from us; their Responsible Person signs it in on arrival; the rare-disease team dispenses to the named patient under the local access pathway.
What the importer gets
A batch of orphan-grade product on a cold-chain validated pallet, with every document an EAMS / compassionate-use / named-patient regulator might ask for — prepared at the Indian end, cross-checked before dispatch, shared electronically ahead of arrival.
Why a rare-disease desk phones us.
Local pack discontinued
An orphan medicine's commercial pack has been withdrawn from the local market — usually because the launch volumes were marginal — but a population of established patients remains on therapy. The named-patient route, supplied from a continuing Indian manufacturing line, bridges them. We hold lines on rare-disease molecules across haematology, neurology, endocrine and metabolic disease.
Strength gap
A paediatric rare-disease patient needs a 5mg or 10mg presentation that the local commercial pack does not produce. Where an Indian manufacturer routinely produces that strength for other regulated markets — or where compounding from a higher-strength base is documented and validated — single-batch supply is sourceable.
Compassionate-use bridging
An EAMS or compassionate-use programme runs ahead of full marketing authorisation. The molecule is approved in another jurisdiction but pending in the destination market. M Care supplies the manufacturer-side document pack a compassionate-use scheme operator needs to import a single-patient or small-cohort batch under the local exception.
Reference-listed product mismatch
An orphan drug is supplied in the destination market only via a single licensed brand, and that brand has stocked out. An Indian-manufactured equivalent — bioequivalent, WHO-GMP, with the right CoA and CoPP — keeps the patient on therapy without switching molecule.
Every form a rare-disease importer's Responsible Person asks for.
Prepared at the Indian end and cross-checked before dispatch. Shared electronically ahead of arrival, physically in the carton.
Batch-specific CoA
HPLC assay, impurity profile, water content, residual solvents, sterility and endotoxin where applicable. Signed by the manufacturer's QC head. Reference standard and method cited.
CoPP, WHO format
Certificate of Pharmaceutical Product issued by CDSCO, in WHO Certification Scheme format. Apostilled at Indian MEA where the destination importer or compassionate-use scheme requests it.
WHO-GMP certificate
Current site-specific WHO-GMP certificate for the manufacturing facility and the specific dosage form. Six-month minimum residual validity at the point of dispatch.
Manufacturing licence
Form 25 / 28 (as applicable) copy, notarised. Confirms the Indian site's authority to manufacture and export the specific dosage form of the orphan molecule.
Compassionate-use attachment
Manufacturer-side fields of the destination compassionate-use or EAMS notification, prepared so the scheme operator's regulatory team only completes the local fields.
Cold-chain logs on arrival
Pre-shipment thermal validation per shipper; continuous logging in transit; on-arrival logger read-out issued before the consignment is opened. Excursion CAPA opened pre-dispatch as a precautionary protocol.
Molecule · indication · patient count · target dispatch. One working day.
- Send the specifics. Molecule (INN), strength, dosage form, patient count or course length, the destination access pathway (EAMS / compassionate-use / named-patient / formulary import) and the target arrival window.
- Availability and price at source. We confirm the Indian manufacturer, batch availability, expiry, CoPP status and a landed price to the destination importer's nominated warehouse. Where the molecule is rare-stocked we'll confirm a manufacture-to-order timeline.
- Pre-dispatch document pack. CoA, CoPP, GMP, licence, manufacturer declaration and the local compassionate-use / EAMS attachment. Shared electronically for the destination Responsible Person and the access-pathway regulator to review before the carton ships.
- Cold-chain dispatch and arrival. Temperature-validated shipper, continuous logging, on-arrival logger read-out, Responsible Person sign-off. Pharmacy-ready.
- Pharmacovigilance and registry. A named PV contact is opened for the consignment's shelf life. Where the access pathway requires a treatment registry (typical for rare-disease cohorts), the contact bridges the registry coordinator and the manufacturer's QA team for the duration of patient follow-up.
Orphan drug supply — the specifics.
Are you an MHRA / EMA / SFDA registered orphan drug holder?
No. We are the Indian manufacturer-side partner. The destination importer must hold the local Wholesale Dealer's Licence with the unlicensed-medicine or compassionate-use authorisation. We supply product and documentation into that import chain; we do not hold a destination-country licence ourselves.
What is the minimum order for an orphan drug?
There is no hard minimum. Single-vial and single-patient consignments are supported where the molecule is in manufacturer stock. Most rare-disease named-patient consignments are 1-20 doses or units.
What's the lead time for a rare-disease order?
Stock-on-hand orphan molecules: 10-15 calendar days door-to-door. Manufacture-to-order batches or unusual strengths: 6-12 weeks (rare-disease lines are often campaign-batched, not continuous-stocked). Urgent single-patient supply has been moved in under 7 days with the right manufacturer prioritisation.
Can you handle the cold-chain for a biological orphan medicine?
Yes. Many rare-disease biologics (enzyme replacement therapies, monoclonal antibodies, gene-therapy adjuncts) require strict 2-8°C or -20°C handling. We run continuous-logged active or vacuum-insulated passive shippers, with pre-shipment thermal validation and on-arrival CAPA.
Which rare-disease therapeutic areas do you cover?
Haematology (haemophilia concentrates, sickle-cell, multiple myeloma adjuncts), metabolic disease (lysosomal storage, mitochondrial), neurology (SMA, Duchenne, neuromuscular), oncology rare cancers, paediatric metabolic, and selected rare cardiovascular and dermatological orphans. Specifics on enquiry.
Do you participate in patient access programmes (NORD-equivalent)?
Yes, on the manufacturer-side. A NORD-equivalent rare-disease NGO or a hospital-led patient access programme can use M Care as its India-end sourcing arm, with the destination importer handling the local regulatory pathway.
Can you supply during a global orphan medicine shortage?
Yes — when the bottleneck is finished-dose manufacturing capacity, an Indian WHO-GMP source often closes the gap inside one to four weeks. We hold lines across rare-disease therapeutic areas and can typically quote a replacement strength or presentation within one working day.
How is pharmacovigilance handled across multiple jurisdictions?
A named PV contact is opened in the destination supply chain for the consignment's shelf life. ADR reports route back to the manufacturer's QA and to CDSCO. Where the access pathway requires registry-aligned PSUR submissions, those compile to ICH E2C and route to the destination authority.
A rare disease, a patient, a molecule the local pack doesn't carry. That's the conversation.
Molecule, indication, patient count, destination access pathway. We'll have a manufacturer-side answer inside one working day.